{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-23-000081","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.699097+00:00","generated_at":"2026-06-08T07:28:20.483443+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tarsus reports Q3 net loss $39.1M; XDEMVY launch yields $1.7M in 5 weeks","bullets":["Net product sales of XDEMVY were $1.7M with ~1,700 bottles dispensed in first 5 weeks post-launch.","Net loss of $39.1M ($1.28 per share) vs. $22.5M loss ($0.84) in Q3 2022; SG&A rose to $30.3M on launch costs.","Gross-to-net discount on XDEMVY was 73%, better than anticipated; cash, equivalents and marketable securities $246.9M.","Received $99.4M net proceeds from August 2023 public equity offering; balance sheet strengthened.","XDEMVY added to AAO Preferred Practice Pattern guidelines as first FDA-approved therapy for Demodex blepharitis."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-23-000081","json":"https://secwatch.observer/filing/0001819790-23-000081.json","markdown":"https://secwatch.observer/filing/0001819790-23-000081.md","text":"https://secwatch.observer/filing/0001819790-23-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000081/0001819790-23-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000081/tars-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:28:20.483443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ecd720d97fb3fde5752615f301fcb0db20a587d6","claim":"Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: revenue $1.9 million, net income $(1.28), EPS $(1.28).","evidence_excerpt":"Gland Disease ● TP-04 Topline Phase 2a (Galatea) Rosacea ● TP-05 Topline Phase 2a (Carpo) Lyme Disease Prevention ● Third Quarter 2023 Financial Results • Total revenues were $1.9 million, driven primarily by $1.7 million in net product sales, representing five weeks of sales following the launch of XDEMVY in late August. • Cost of sales were $0.4 million, due","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000081/0001819790-23-000081-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$1.9 million"},{"label":"Net income","value":"$(1.28)"},{"label":"EPS","value":"$(1.28)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}